Pascal Soriot, AstraZeneca CEO (Chris Kleponis/picture-alliance/dpa/AP Images)

UK says it won't pur­chase As­traZeneca's Covid treat­ment due to 'in­suf­fi­cien­t' Omi­cron da­ta — re­ports

Weeks af­ter ev­i­dence sug­gest­ed cur­rent Omi­cron sub­vari­ants may be less sus­cep­ti­ble to As­traZeneca’s pro­phy­lac­tic Covid-19 treat­ment Evusheld, the UK has re­port­ed­ly de­cid­ed against buy­ing dos­es for now.

The UK’s De­part­ment of Health said it won’t pro­cure Evusheld dos­es due to “in­suf­fi­cient da­ta on the du­ra­tion of pro­tec­tion of­fered by Evusheld in re­la­tion to the omi­cron vari­ant,” ac­cord­ing to the BMJ, a peer-re­viewed trade jour­nal pub­lished by the British Med­ical As­so­ci­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.